FIELD: biotechnology.
SUBSTANCE: there are presented: a binding agent comprising at least two binding domains which bind to two different receptors from the TNF superfamily. Also disclosed are a nucleic acid molecule coding a binding agent, a cell for expressing the binding agent, a pharmaceutical composition, and a kit.
EFFECT: invention is used to treat diseases related to OX40.
12 cl, 9 tbl, 13 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| NEONATAL Fc RECEPTOR BINDING AFFIMERS | 2020 |
|
RU2817008C1 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| BISPECIFIC ANTIBODIES | 2020 |
|
RU2818588C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ELEMENTS THAT BIND TO IL-1 BETA | 2013 |
|
RU2711118C2 |
| IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| IL-17A-BINDING POLYPEPTIDES | 2016 |
|
RU2749712C2 |
